LinkedIn Profile

Access Xanodyne historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:xanodyne 35551 Jun 4th, 2019 12:00AM Xanodyne Pharmaceuticals 3.0K 56.00 Open Pharmaceuticals Jun 4th, 2019 02:59PM Jun 4th, 2019 02:59PM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Open Pain Management and Women's Health Open One Riverfront Plaza Newport Kentucky US Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 17th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 16th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 15th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 14th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 13th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 12th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 11th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 10th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology
private:xanodyne 35551 Feb 9th, 2018 12:00AM Xanodyne Pharmaceuticals 2.9K 57.00 Open Pharmaceuticals Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. Xanodyne Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.